DETAILED ACTION
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
2. Claims 1-6 and 14-17 are currently pending.
Election/Restrictions
3. Applicant’s election without traverse of Group II, claims 14-17, Garcinia cambogia extract for species A, chiisanogenin for species B, and non-alcoholic fatty liver disease for species C in the reply filed on December 8, 2025 is acknowledged. The search of the prior art has determined that chiisanogenin for species B is free of the art. Claims 14-17 would be considered free of the art if they were limited to this species. The search and examination has been extended to the additional species of Acanthopanax extract for species B and liver cancer for species C. See MPEP section 803.02.
4. Claims 1-6 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.
5. Claims 14-17 are examined on the merits.
Claim Objections
6. Claim 14 is objected to because of the following informalities: this claim depends from non-elected claim 1. If the non-elected claims are cancelled, claim 14 will be incomplete. Appropriate correction is required.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
7. Claim(s) 14-17 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Li (CN 102078569 A – English translation) with “Garcinia cambogia” article (https://foodfitness.in/garcinia-cambogia/ - June 24, 2020) providing definitions.
Li teaches a method for treating liver cancer by administering a single composition comprising an extract from Acanthopananx and gamboges (see abstract, paragraphs 14-23, and claims). “Gamboge” is a common name for Garcinia cambogia extract (see “Garcinia cambogia” article).
8. No claims are allowed; however, allowable subject matter is indicated above in paragraph 3.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Hoffman whose telephone number is (571)272-0963. The examiner can normally be reached M-Th 8:30am - 5:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUSAN HOFFMAN/Primary Examiner, Art Unit 1655